Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
The purpose of this study is to find out what effects, good and/or bad, pembrolizumab in combination with trastuzumab and chemotherapy, has on the patients' esophagogastric cancer.
Esophageal Cancer|Gastric Cancer
DRUG: pembrolizumab|DRUG: trastuzumab|DRUG: capecitabine|DRUG: cisplatin|DRUG: Oxaliplatin|DRUG: 5-Fluorouracil
Percentage of Participants With Progression Free Survival, We will define progression of disease per RECIST 1.1 criteria, 6 months
The purpose of this study is to find out what effects, good and/or bad, pembrolizumab in combination with trastuzumab and chemotherapy, has on the patients' esophagogastric cancer.